-

Gilead's Earnings Skyrocket as Florida’s AIDS Drug Program Falters, says AHF

LOS ANGELES--(BUSINESS WIRE)--While Gilead is raking in blowout profits, many state AIDS Drug Assistance Programs (ADAPs) can no longer afford the high prices of its HIV medications. State support programs are scrambling to contain costs as financial analysts await the company’s earnings call for the first quarter of 2026 (Earnings Call, Thursday, May 7th). Low-income patients that rely on state assistance will not share the good news expected by investors.

Last year, HIV product sales were the driving force behind Gilead’s revenue, accounting for 72% of total sales. In 2025, Biktarvy, Gilead’s premier HIV medication regimen, cost $61,000 for a year of treatment.

Share

Last year, HIV product sales were the driving force behind the company’s revenue, accounting for 72% of total sales. Sales of treatments for people living with HIV were up 6% from 2024, totaling $20.8 billion. Biktarvy sales saw a 7% jump from the prior year, generating $14.3 billion in revenue. In 2025, Gilead’s premier HIV medication regimen cost $61,000 for a year of treatment. The prohibitive cost is making the treatment preferred by the majority of patients and their medical prescribers unaffordable for state assistance programs.

Florida is the first state to completely remove Biktarvy from its drug formulary, but likely will not be the last. In fact, 19 states are projecting budget deficits for the upcoming fiscal year. Cost containment measures are the new norm; fiscal reality means states will cover older, less effective drugs for the patients most in need.

Analysts expect a hefty 52% year-over-year earnings per share jump for Gilead in the first quarter of 2026. The prediction is little solace to the low-income patients receiving drugs from lifeline support programs.

AIDS Healthcare Foundation (AHF), the world’s largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 2.9 million individuals across 50 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. In January 2025, AHF received the MLK, Jr. Social Justice Award, The King Center’s highest recognition for an organization leading work in the social justice arena. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, and follow us on Instagram, Twitter, and TikTok.

Contacts

Ged Kenslea, Senior Director, AHF Communications
(323) 791-5526 c ged.kenslea@ahf.org

John Hassell, AHF National Director of Advocacy
(202) 774-4854 c john.hassell@ahf.org

AIDS Healthcare Foundation


Release Summary
Gilead's Earnings per Share Expected to Be Up 52% as Florida’s and other States’ AIDS Drug Programs Falters, says AHF
Release Versions
Hashtags

Contacts

Ged Kenslea, Senior Director, AHF Communications
(323) 791-5526 c ged.kenslea@ahf.org

John Hassell, AHF National Director of Advocacy
(202) 774-4854 c john.hassell@ahf.org

Social Media Profiles
More News From AIDS Healthcare Foundation

Hantavirus Reveals Latin America Is Unprepared, Warns The Lancet Commentary

MEXICO CITY--(BUSINESS WIRE)--The Latin American Technical Working Group, composed of former health ministers from the region, public health experts, epidemiologists, academics, and civil society representatives, published a new comment in The Lancet arguing that Latin America urgently needs a regional rapid-response platform to prevent, prepare for, and respond to infectious threats. Read the full text in The Lancet here. The comment, written collectively by the Technical Working Group, takes...

AHF Welcomes Lula–Tedros Call for Equity in Pandemic Agreement, Warns against Rushing Empty Deal

MIAMI, GENEVA & SÃO PAULO--(BUSINESS WIRE)--The AIDS Healthcare Foundation (AHF) and the AHF Global Public Health Institute welcome the open letter issued by President Luiz Inácio Lula da Silva of Brazil and World Health Organization Director-General Dr. Tedros Adhanom Ghebreyesus on the occasion of the G7 Summit, calling on the leaders of the G7, G20, BRICS, and all nations to finish the Pathogen Access and Benefit-Sharing (PABS) annex of the WHO Pandemic Agreement. AHF particularly commends t...

AHF: Ebola Outbreak Exposes Need for Stronger Investment in Preparedness

KAMPALA, Uganda--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) calls for stronger investments in Ebola preparedness and response as the current outbreak in the Democratic Republic of the Congo and Uganda underscores the continued threat posed by the deadly disease and the urgent need to strengthen public health systems across Africa. The outbreak is caused by the Bundibugyo virus strain, for which there is currently no approved vaccine or specific treatment. While progress has been made in...
Back to Newsroom